IPI-GLIO Immunotherapy Appeal
There is an urgent need for new treatments to improve clinical outcomes and survival for patients with glioblastoma.
Glioblastoma is the most common type of primary, malignant and very aggressive brain tumour with around 2,200 cases diagnosed each year in England.
Standard treatment usually involves surgery (if possible) to remove the tumour. This is often followed by radiotherapy and chemotherapy.
Dr Paul Mulholland is a consultant medical oncologist at The National Hospital for Neurology and Neurosurgery (UCLH). He is very optimistic about new treatments including immunotherapy for treating glioblastoma. An immunotherapy drug, ipilimumab has been approved for use in patients with advanced melanoma and brain metastases (secondary tumours). More than 18% of patients who received this immunotherapy drug in a clinical trial were alive after five years compared to only 8% who did not.
The trial will involve seven UK sites: Addenbrookes Hospital, Cambridge, Churchill Hospital, Oxford, Guy’s Hospital, London, Mount Vernon Cancer Centre, Northwood, The Christie, Manchester, University College Hospital, London and Western General Hospital, Edinburgh.
The National Brain Appeal has committed to raise £250,000 to support the running costs of the trial.
What we fund
Leave a legacy
Subscribe to our e-letter or newspaper
GET IN TOUCH
The National Brain Appeal
26/27 Boswell Street
London WC1N 3JZ
020 3448 4724
Registered Charity No. 290173. A limited company registered in England. No. 01844281